Ephedra. (English) Zbl 1100.62619

Summary: In February 2004, the U.S. Food and Drug Administration (FDA) prohibited the sale of dietary supplements containing ephedrine alkaloids (ephedra), stating that such supplements present an unreasonable risk of illness or injury. The Dietary Supplement Health and Education Act (DSHEA) of 1994 (21 USC §301, 1994) governs dietary supplement regulation in the U.S. DSHEA places the burden of proof for safety on the government rather than on the manufacturer and thus differs significantly from regulations that govern the marketing of drugs. Part of the evidence the FDA used in reaching its decision was a systematic review of the efficacy and safety of ephedra conducted by the Southern California Evidence-Based Practice Center. In addition to a meta-analysis of controlled trial data, the review contained an evaluation of observational case report data, a study design that has limited inferential abilities regarding cause and effect.
How did the FDA decide what data were relevant to its decision? How did the FDA argument for the ban differ from a decision based solely on statistical hypothesis testing? This paper will address these questions by describing the systematic review approach, the evidence presented, the interpretation of that evidence by those on both sides of the argument and the process by which the decision was made.


62P10 Applications of statistics to biology and medical sciences; meta analysis
Full Text: DOI


[1] USC §301 (1994). Dietary Supplement Health and Education Act of 1994, Title 21, Section 301.
[2] Bodley, H. (2003). Medical examiner: Ephedra a factor in Bechler death. USA Today , March 13.
[3] CNN.com (2003). FDA plans warning labels for ephedra. CNN.com. March 2, 2003; accessed July 16, 2004. Available at www.cnn.com/2003/HEALTH/diet.fitness/02/28/ ephedra.fda.
[4] Col, N. F. and Pauker, S. G. (2003). The discrepancy between observational studies and randomized trials of menopausal hormone therapy: Did expectations shape experience? Annals of Internal Medicine 139 923–929.
[5] Committee on the Framework for Evaluating the Safety of Dietary Supplements (2004). Dietary Supplements: A Framework for Evaluating Safety . National Academies Press, Washington.
[6] Crawford, L. M. (2002). Statement of Lester M. Crawford, D. V. M., Ph.D., Deputy Commissioner, Food and Drug Administration. October 8, 2002. Committee on Governmental Affairs, United States Senate, Subcommittee on Oversight of Government Management, Restructuring and the District of Columbia.
[7] Cytel Software Corporation (2000). StatExact 4 for Windows, Version 4.0.
[8] DerSimonian, R. and Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials 7 177–188.
[9] Durbin, R. (2003). Durbin moves to prevent sale of dangerous dietary supplements like ephedra. Press release, March 26, 2003. U.S. Senator Dick Durbin, Washington. Available at durbin.senate.gov/ durbin/new2001/press/2003/03/ 2003328821.html.
[10] Ephedra Education Council (2003). Industry Supports HHS and FDA Call for Science-Based Regulations, Ephedra Education Council, Washington, February 28, 2003. Available at www.npicenter.com/index.asp?action=NBViewDoc& DocumentID=4052.
[11] FDA (2003a). Fact sheet. HHS acts to reduce safety concerns associated with dietary supplements containing ephedra. U.S. Food and Drug Administration, Rockville, MD. February 28, 2003. Available at www.fda.gov/bbs/topics/NEWS/ ephedra/factsheet.html.
[12] FDA (2003b). HHS acts to reduce potential risks of dietary supplements containing ephedra. U.S. Food and Drug Administration, Rockville, MD. February 28, 2003. Available at www.fda.gov/bbs/topics/NEWS/2003/NEW00875.html.
[13] FDA (2004a). FDA news: FDA issues regulation prohibiting sale of dietary supplements containing ephedrine alkaloids and reiterates its advice that consumers stop using these products. February 6, 2004.
[14] FDA (2004b). MedWatch. The FDA safety and information adverse event reporting program. July 13, 2004.
[15] FDA (2004c). Dietary supplements containing ephedrine alkaloids final rule summary. U.S. Food and Drug Administration. July 15, 2004.
[16] Fontanarosa, P. B., Rennie, D. and DeAngelis, C. D. (2003). The need for regulation of dietary supplements—Lessons from ephedra. J. American Medical Association 289 1568–1570.
[17] Glass, G. V. (1976). Primary, secondary and meta-analysis of research. Educational Researcher 5 (10) 3–8.
[18] HHS (2002). HHS announces plans to study ephedra; steps up enforcement of illegal ephedrine marketing. U.S. Department of Health & Human Services, Washington. June 14, 2002. Available at www.hhs.gov/news/press/2002pres/ 20020614.html.
[19] Huff, D. (1954). How to Lie with Statistics . Norton, New York.
[20] Kubatko, R. (2003). Oriole pitching prospect dies; Bechler, 23, had multi-system organ failure caused by heatstroke after leaving workouts on Sunday. Los Angeles Times , February 18, p. D1.
[21] Morgenstern, L. B., Viscoli, C. M., Kernan, W. N., Brass, L. M., Broderick, J. P., Feldmann, E., Wilterdink, J. L., Brott, T. and Horwitz, R. I. (2003). Use of ephedra-containing products and risk for hemorrhagic stroke. Neurology 60 132–135.
[22] Newhan, R. (2002). Kile’s death stuns baseball. Los Angeles Times , June 23, p. D1.
[23] Olkin, I. (1996). Meta-analysis. Current issues in research synthesis. Statistics in Medicine 15 1253–1257.
[24] Pugmire, L. (2002). Exam points to Kile’s heart. Los Angeles Times , June 24, p. D1.
[25] Redfearn, S. (2003). Ephedra products thin out. The Washington Post , January 14, p. F1.
[26] Shekelle, P. G., Hardy, M. L., Morton, S. C., Maglione, M., Mojica, W. A., Suttorp, M. J., Rhodes, S. L., Jungvig, L. and Gagné, J. (2003). Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance. A meta-analysis. J. American Medical Association 289 1537–1545.
[27] Shekelle, P. G., Morton, S. C., Maglione, M. et al. (2003). Ephedra and ephedrine for weight loss and athletic performance enhancement: Clinical efficacy and side effect. Evidence Report/Technology Assessment No. 76. Agency for Healthcare Research and Quality, Publication No. 03-E022, Rockville, MD.
This reference list is based on information provided by the publisher or from digital mathematics libraries. Its items are heuristically matched to zbMATH identifiers and may contain data conversion errors. In some cases that data have been complemented/enhanced by data from zbMATH Open. This attempts to reflect the references listed in the original paper as accurately as possible without claiming completeness or a perfect matching.